Congress has intensified its interest in opening a regulatory pathway for follow-on biologics (FOBs).  Strongly supported by some healthcare organizations, with other healthcare stakeholders expressing reservations, FOBs raise critical legislative, clinical, budgetary, and marketplace dynamic questions.  Given the rapid growth of biologic product use in the US market, FOBs' potential entry into the marketplace has become a significant issue for patients, providers, manufacturers, and payers.

This 90-minute, interactive audio conference will discuss:

• Current legislative activity on FOBs
• The unique features of biologic products that distinguish them from small-molecule drugs, and how these features might affect legislative and regulatory action
• Assessment of the likely budgetary impact of FOBs and the key assumptions underlying differing estimates
• How FOB entry into the marketplace might impact manufacturers, payers, and patients over the short- and longer-term.

Register

• Jon Glaudemans, Senior Vice President, Avalere Health
• Walter Moore, Vice President of Government Affairs, Genentech
• Mesfin Tegenu, President, PerformRx
• Alexis Ahlstrom, Senior Manager, Avalere Health

Registration Prices :
Commercial	$375
Government	$250
Avalere Client	$300
Non-profit	Special rates apply.*

*For information, please call Rebecca Elkanick at 202.207.3831 or email relkanick@avalerehealth.net.

Cancellation Policy: To receive a refund, notice is required at least seven business days prior to the audio conference. With proper notice, fees are refunded minus a $40 service fee. No refunds are given for cancellations received with less than seven days notice. Avalere Health reserves the right to cancel or reschedule an audio conference due to unforeseen circumstances.